92.95
1.55 (1.70%)
| Penutupan Terdahulu | 91.40 |
| Buka | 92.78 |
| Jumlah Dagangan | 1,153,073 |
| Purata Dagangan (3B) | 1,221,366 |
| Modal Pasaran | 8,686,365,696 |
| Harga / Buku (P/B) | 8.14 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2026 |
| EPS Cair (TTM) | -3.06 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.06% |
| Nisbah Semasa (MRQ) | 8.06 |
| Aliran Tunai Operasi (OCF TTM) | -169.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -68.57 M |
| Pulangan Atas Aset (ROA TTM) | -25.34% |
| Pulangan Atas Ekuiti (ROE TTM) | -65.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Spyre Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -1.17 |
|
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 8.71% |
| % Dimiliki oleh Institusi | 106.07% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |